Mutual of America Capital Management LLC Has $198,000 Holdings in Progyny, Inc. (NASDAQ:PGNY)

Mutual of America Capital Management LLC decreased its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 75.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,812 shares of the company's stock after selling 35,620 shares during the quarter. Mutual of America Capital Management LLC's holdings in Progyny were worth $198,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PGNY. Price T Rowe Associates Inc. MD increased its stake in shares of Progyny by 5.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 54,912 shares of the company's stock worth $2,095,000 after purchasing an additional 2,947 shares during the period. Janus Henderson Group PLC boosted its position in shares of Progyny by 2.2% in the first quarter. Janus Henderson Group PLC now owns 307,909 shares of the company's stock valued at $11,745,000 after acquiring an additional 6,549 shares during the period. Comerica Bank increased its position in Progyny by 5.3% during the first quarter. Comerica Bank now owns 67,547 shares of the company's stock worth $2,577,000 after acquiring an additional 3,428 shares during the period. Cetera Advisors LLC acquired a new stake in Progyny in the 1st quarter worth about $321,000. Finally, Cambridge Trust Co. bought a new stake in Progyny in the 1st quarter valued at about $95,000. 94.93% of the stock is owned by institutional investors.

Progyny Price Performance

PGNY stock traded up $0.09 during trading on Friday, reaching $15.57. 572,197 shares of the company were exchanged, compared to its average volume of 1,400,833. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of 26.85, a P/E/G ratio of 1.79 and a beta of 1.44. The company has a 50-day moving average of $15.82 and a two-hundred day moving average of $22.22. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The company had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. During the same period in the previous year, the firm posted $0.16 EPS. The business's quarterly revenue was up 2.0% compared to the same quarter last year. On average, analysts forecast that Progyny, Inc. will post 0.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PGNY. Barclays cut their price target on Progyny from $30.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Bank of America cut their target price on Progyny from $22.00 to $21.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. JMP Securities cut Progyny from an "outperform" rating to a "market perform" rating in a research report on Thursday, September 19th. Leerink Partners cut their price objective on shares of Progyny from $25.00 to $21.00 and set a "market perform" rating for the company in a research report on Thursday, September 19th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Progyny from $31.00 to $22.00 and set an "overweight" rating on the stock in a research note on Thursday, September 19th. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Progyny currently has a consensus rating of "Hold" and an average target price of $25.42.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.